Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER

Spanish pharmaceuticals firm Grifols reports 30% drop in nine-month profit

Stock Markets Nov 08, 2022 10:22
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The logo of the Spanish pharmaceuticals company Grifols is pictured on their headquarters' building in Sant Cugat del Valles, near Barcelona, Spain, September 17, 2021. REUTERS/Albert Gea
 
GRLS
-0.28%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GRFS
+0.76%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GIKLY
+11.28%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

MADRID (Reuters) - Spanish pharmaceutical company Grifols reported a 30% drop in nine-month net profit on Tuesday, due in part to acquisition costs.

Grifols said it was still on track to meet its full-year financial targets, but its shares fell 4.2% in morning trade.

The company, which uses blood plasma to make medicines, saw its business severely hit by the pandemic as blood collection was halted in many countries.

Brokerage CM Capital Markets said in a note to investors that Grifols' net profit of 188 million euros ($187.7 million) for January-September was below consensus estimates.

Grifols completed its 1.6 billion euro takeover of German rival Biotest in the first half of this year.

The company said its revenue increased 9.5% to 4.4 billion euros in the first nine months of the year, thanks to a positive performance of its biopharma department and a 25% increase in plasma collections.

The operating results were above expectations, CM Capital Markets said.

Grifols said it expects to keep reducing its net debt down to 7.9 times earnings before interest, taxes, depreciation and amortization (EBITDA) by the end of the year.

Its net debt stood at 9.4 billion euros in September, or 8.6 times its EBITDA, slightly less than the 9 times EBITDA at the end of June.

Last month Grifols appointed a new executive chairman as it seeks to revive investor confidence after its shares dropped by almost half this year.

Grifols has said the current share price does not support a capital increase.

($1 = 1.0016 euros)

Spanish pharmaceuticals firm Grifols reports 30% drop in nine-month profit
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email